SCHEMBL29920552

SCHEMBL29920552

C[C@@H]1COc2ccccc2[C@H]1CS(N)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.42
SMN1; SMN2 Q16637 1/20 0.39
LTB4R Q15722 1/20 0.38
LTB4R2 Q9NPC1 1/20 0.38
CYP2D6 P10635 3/20 0.36
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 1/20 0.36
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
CYP3A4 P08684 1/20 0.34
HCRTR2 O43614 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HTR2C P28335 1/20 0.34
KCNH2 Q12809 1/20 0.34
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29920570 1.00 CA2 (0.42) CA2SMN1; SMN2LTB4RLTB4R2CYP2D6
SCHEMBL15451666 0.84 LTB4R (0.41) LTB4RLTB4R2CYP2D6SLC6A2SLC6A4
SCHEMBL29920646 0.81 CA2 (0.43) CA2LTB4RLTB4R2HCRTR2DRD2
SCHEMBL29920642 0.81 CA2 (0.43) CA2LTB4RLTB4R2HCRTR2DRD2
SCHEMBL29920587 0.77 CA2 (0.32) CA2LTB4RLTB4R2
SCHEMBL29920659 0.77 CA2 (0.32) CA2LTB4RLTB4R2
SCHEMBL29920510 0.77 CA2 (0.32) CA2LTB4RLTB4R2
SCHEMBL442639 0.73 CA2 (0.63) CA2SMN1; SMN2LTB4RLTB4R2SLC6A2
SCHEMBL22248036 0.72 HTT (0.54) SMN1; SMN2LTB4RLTB4R2HCRTR2ALDH1A1
SCHEMBL25244697 0.72 SLC6A2 (0.40) LTB4RLTB4R2CYP2D6SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022217248-A1 SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2022-10-13 WO disclosed